Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Top Pharmaceutical Stocks To Follow Now – November 2nd
03:05am, Tuesday, 04'th Nov 2025
Eli Lilly and Company, Pfizer, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded compani
My Favorite Dividend King to Buy in November
07:30am, Monday, 03'rd Nov 2025
AbbVie has increased its dividend for 53 consecutive years and more than quadrupled its dividend since 2013. The drugmaker has a clear growth runway thanks to rising stars in its lineup and a promisin
2 Magnificent Dividend Stocks to Buy and Hold Forever
09:15am, Sunday, 02'nd Nov 2025
Investing in strong dividend stocks is a great way to earn better-than-average long-term returns. AbbVie has a reliable, non-cyclical business and a long and impressive track record of dividend growth
ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November
11:15pm, Saturday, 01'st Nov 2025
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with o
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
12:36pm, Saturday, 01'st Nov 2025
AbbVie Inc. NYSE: ABBV delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock to mak
Best Dividend Aristocrats For November 2025
10:25am, Saturday, 01'st Nov 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW
Why AbbVie Stock Flopped on Friday
06:15am, Saturday, 01'st Nov 2025
Despite the pharmaceutical giant's beat-and-raise third quarter, investors were expecting better. Profitability guidance, even though it was raised, came in under analyst estimates.
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
03:56pm, Friday, 31'st Oct 2025
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board J
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
03:21pm, Friday, 31'st Oct 2025
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
12:20pm, Friday, 31'st Oct 2025
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
12:20pm, Friday, 31'st Oct 2025
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
11:47am, Friday, 31'st Oct 2025
AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.
AbbVie: Why Q3 Confirms Its Immunology Dominance
10:39am, Friday, 31'st Oct 2025
AbbVie Inc., 2 hours ago, published monstrous results for Q3, once again strengthening my confidence that it is a "powerhouse" in the autoimmune disease drugs market. Net revenues from AbbVie's immuno
AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates
10:00am, Friday, 31'st Oct 2025
AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago.
5 Dividend ETFs That Could Pay You for Life
09:02am, Friday, 31'st Oct 2025
Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.
